These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1748141)

  • 81. ORG 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man.
    Bradbrook ID; Magnani HN; Moelker HC; Morrison PJ; Robinson J; Rogers HJ; Spector RG; Van Dinther T; Wijnand H
    Br J Clin Pharmacol; 1987 Jun; 23(6):667-75. PubMed ID: 3606928
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Time courses of the antithrombotic effects, bleeding enhancing effects and interactions with factors Xa and thrombin after administration of low molecular weight heparinoid Org 10172 or heparin to rats.
    Hobbelen PM; Vogel GM; Meuleman DG
    Thromb Res; 1987 Dec; 48(5):549-58. PubMed ID: 3481660
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Pharmacokinetic interactions with digoxin.
    Rodin SM; Johnson BF
    Clin Pharmacokinet; 1988 Oct; 15(4):227-44. PubMed ID: 3056649
    [TBL] [Abstract][Full Text] [Related]  

  • 84. What is the best plasmatic activity which could be correlated with the antithrombotic effect of heparin and a low molecular weight heparin fragment?
    Doutremepuich C; Castrioto T; De Seze O; Pereira F; Doutremepuich F; Anne MC; Toulemonde F
    Thromb Res; 1987 Oct; 48(2):245-51. PubMed ID: 2827341
    [No Abstract]   [Full Text] [Related]  

  • 85. Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers.
    Stiekema JC; Wijnand HP; Van Dinther TG; Moelker HC; Dawes J; Vinchenzo A; Toeberich H
    Br J Clin Pharmacol; 1989 Jan; 27(1):39-48. PubMed ID: 2468354
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in post-surgical patients treated with either Logiparin (LMWH) or unfractionated heparin. Post-surgery Logiparin Study Group.
    Bara L; Leizorovicz A; Picolet H; Samama M
    Thromb Res; 1992 Mar; 65(4-5):641-50. PubMed ID: 1319619
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses.
    Koup JR; Greenblatt DJ; Jusko WJ; Smith TW; Koch-Weser J
    J Pharmacokinet Biopharm; 1975 Jun; 3(3):181-92. PubMed ID: 1159622
    [No Abstract]   [Full Text] [Related]  

  • 88. Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III.
    Teien AN; Lie M
    Thromb Res; 1977 Mar; 10(3):399-410. PubMed ID: 854877
    [No Abstract]   [Full Text] [Related]  

  • 89. Digoxin metabolism in patients.
    Peters U; Falk LC; Kalman SM
    Arch Intern Med; 1978 Jul; 138(7):1074-6. PubMed ID: 666466
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-pNA (S-2238).
    Larsen ML; Abildgaard U; Teien AN; Gjesdal K
    Thromb Res; 1978 Aug; 13(2):285-8. PubMed ID: 567858
    [No Abstract]   [Full Text] [Related]  

  • 91. Interaction of ORG 10172, a low molecular weight heparinoid, and digoxin in healthy volunteers.
    de Boer A; Stiekema JC; Danhof M; Moolenaar AJ; Breimer DD
    Eur J Clin Pharmacol; 1991; 41(3):245-50. PubMed ID: 1748141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]     [New Search]
    of 5.